87478-74-8

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dichloro-6-ethyl-Thieno[2,3-d]pyrimidine is used as a key intermediate in the synthesis of pharmaceutical drugs and compounds. Its unique chemical structure allows it to be a versatile building block for the creation of new medications.
Used as an Antifungal Agent:
In the field of antifungal applications, 2,4-dichloro-6-ethyl-Thieno[2,3-d]pyrimidine is utilized for its potential to combat fungal infections. Its chemical properties enable it to target and inhibit the growth of fungi, making it a promising candidate for the development of antifungal treatments.
Used as an Antibacterial Agent:
Similarly, in the antibacterial domain, 2,4-dichloro-6-ethyl-Thieno[2,3-d]pyrimidine is employed for its capacity to fight bacterial infections. Its ability to interfere with bacterial growth and survival contributes to its potential use in the formulation of new antibacterial drugs.
Used in the Treatment of Diseases and Infections:
Beyond its direct applications, 2,4-dichloro-6-ethyl-Thieno[2,3-d]pyrimidine is also used in the broader context of disease and infection treatment. Its incorporation into pharmaceutical formulations can lead to the development of treatments for a variety of conditions caused by microbial pathogens.

Upstream product

• 19156-63-9 2-amino-5-ethylthiophene-3-carboxylic acid methyl ester 
• 502649-08-3 6-ethylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 502649-08-3 6-ethylthieno[2,3-d]pyrimidine-2,4-diol 

Downstream Products

• 502644-42-0 2-chloro-6-ethyl-4-[4-(phenylacetyl)piperazin-1-yl]thieno[2,3-d]pyrimidine 
• 911214-75-0 2-azido-4-[4-(1,1'-biphenyl-4-ylcarbonyl)piperazin-1-yl]-6-ethylthieno[2,3-d]pyrimidine 
• 911214-76-1 4-[4-(1,1'-biphenyl-4-ylcarbonyl)piperazin-1-yl]-6-ethylthieno[2,3-d]pyrimidin-2-amine 
• 902765-53-1 4-[4-(1,1'-biphenyl-4-ylcarbonyl)piperazin-1-yl]-2-chloro-6-ethylthieno[2,3-d]pyrimidine 
• 902765-64-4 4-[4-(1,1'-biphenyl-3-ylcarbonyl)piperazin-1-yl]-2-chloro-6-ethylthieno[2,3-d]pyrimidine 

Relevant academic research and scientific papers

Novel Thienopyrimidine-Based PET Tracers for P2Y12Receptor Imaging in the Brain

The P2Y12 receptor (P2Y12R) is uniquely expressed on microglia in the brain, and its expression level directly depends on the microglial activation state. Therefore, P2Y12R provides a promising imaging marker for distinguishing the pro- and anti-inflammatory microglial phenotypes, both of which play crucial roles in neuroinflammatory diseases. In this study, three P2Y12R antagonists were selected from the literature, radiolabeled with carbon-11 or fluorine-18, and evaluated in healthy Wistar rats. Brain imaging was performed with and without blocking of efflux transporters P-glycoprotein and breast cancer resistance protein using tariquidar. Low brain uptake in healthy rats was observed for all tracers at baseline conditions, whereas blocking of efflux transporters resulted in a strong (6-7 fold) increase in brain uptake for both of them. Binding of the most promising tracer, [18F]3, was further evaluated by in vitro autoradiography on rat brain sections, ex vivo metabolite studies, and in vivo P2Y12R blocking studies. In vitro binding of [18F]3 on rat brain sections indicated high P2Y12R targeting with approximately 70% selective and specific binding. At 60 min post-injection, over 95% of radioactivity in the brain accounted for an intact tracer. In blood plasma, still 40% intact tracer was found, and formed metabolites did not enter the brain. A moderate P2Y12R blocking effect was observed in vivo by positron emission tomography (PET) imaging with [18F]3 (p = 0.04). To conclude, three potential P2Y12R PET tracers were obtained and analyzed for P2Y12R targeting in the brain. Unfortunately, the brain uptake appeared low. Future work will focus on the design of P2Y12R inhibitors with improved physicochemical characteristics to reduce efflux transport and increase brain penetration.

Thienopyrimidine-based P2Y12 platelet aggregation inhibitors

Herein we describe the design and synthesis of a novel series of potent thienopyrimidine P2Y12 inhibitors and the negative impact protein binding has on the inhibition of platelet aggregation.

THIENO[2,3-d]PYRIMIDINE COMPOUNDS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1, A2, A3, A4, A5, A6, A7, A

4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1 , A2, A3, A4, A5, A6, A7, Asup

4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A1, A2, A3, A4, A5, A6, A7, As

THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.